

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

September 28, 2020

Douglas J. Devine Chief Financial Officer iRhythm Technologies, Inc. 699 8th Street, Suite 600 San Francisco, CA 94103

> Re: iRhythm Technologies, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed March 2, 2020

Form 10-Q for the Quarterly Period Ended June 30, 2020 Filed August 7, 2020

File No. 001-37918

Dear Mr. Devine:

We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments.

Form 10-Q for the Quarterly Period Ended June 30, 2020

Item 6. Exhibits, page 70

1. We note that the certifications filed as Exhibits 31.1 and 31.2 exclude the introductory language regarding internal control over financial reporting in the fourth paragraph and do not include paragraph 4(b). Please amend the filing to provide revised certifications that include the required information. You may file an abbreviated amendment that is limited to the cover page, explanatory note, signature page and paragraphs 1, 2, 4 and 5 of the certifications. Refer to Exchange Act Rule 13a-14(a) and Item 601(b)(31) of Regulation S-K. This comment also applies to your Form 10-Q for the quarterly period ended March 31, 2020.

Douglas J. Devine iRhythm Technologies, Inc. September 28, 2020 Page 2

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Eric Atallah at (202) 551-3663 or Lynn Dicker, Senior Accountant, at (202) 551-3616 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences